XLIFE-SCIENCES-AG
10.6.2021 08:08:07 CEST | Business Wire | Press release
Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R) reduces the viral load by 90% and acts against infection-related inflammatory processes without developing a resistance. It is already used on humans. The active pharmaceutical ingredient ProcCluster(R) developed by inflamed pharma GmbH is membrane permeable and is based on the active ingredient procaine. It acts both locally as well as systemically and is characterized by a wide range of applications in inflammatory diseases. ProcCluster(R) is already used for various prescription drugs for humans. In various case studies, renowned medical doctors have now been able to successfully demonstrate the effectiveness in the treatment of Covid-19 and Long-Covid patients. In studies with various cell lines, especially lung cells, the active ingredient was able to reduce the viral load by 90% in an early phase and effectively inhibit inflammation in a later phase. These effects can be transferred to other RNA viruses. Oliver R. Baumann, CEO of Xlife Sciences AG, comments: "ProcCluster(R) has enormous market potential because, in contrast to other active ingredients, both the inflammatory processes and the viral load in the body are significantly reduced. This means that it can be used at different points in time during the course of the Covid-19 disease". It is of inestimable value that this active ingredient is already produced by inflamed pharma GmbH in high quality at low cost. "Another key advantage compared to vaccines and antibodies is that ProcCluster(R) does not lead to resistance development and can also be used against virus mutants", continues Baumann. In addition, ProcCluster(R) has a stimulating effect on the microcirculation, which is particularly important for Long-Covid patients. So far, no negative side effects have been observed either. According to the management of Xlife, they are already in various discussions with possible industrial partners in order to have ProcCluster(R) industrially manufactured. The aim is for the active ingredient to be licensed out as quickly as possible. About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1206317 |
| End of Announcement | DGAP News Service |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005992/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age22.10.2026 15:00:00 CEST | Press release
Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022474590/en/ SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TOKYO: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cel
Lenovo Expands AI Library with Proven, Validated Use Cases to Accelerate Business Outcomes and Drive Greater Value Per Token22.10.2026 15:00:00 CEST | Press release
New enterprise AI use cases and research findings show how organizations can move from AI experimentation to measurable value up to 24x faster1 while improving the economics of AISignal65 analysis shows how enterprise customers can lower cost per token by up to 70% at full utilization with on-premises Lenovo Hybrid AI Factories compared to hyperscale API pricing4 Lenovo today expanded the Lenovo AI Library with new, validated AI use cases, extending its portfolio of enterprise-ready solutions that can help organizations move from AI experimentation to measurable business outcomes up to 24x faster1 than custom-built implementations. Now available through the Lenovo AI Library, the added use cases provide proven starting points to accelerate AI deployments and realize returns from investments sooner. Alongside the expansion, new research conducted by The Futurum Group and Signal65 validates how Lenovo’s AI Library, infrastructure and services can help enterprises optimize AI economics fo
Follow-on Order Brings Orders from INNIO Data Center Customer to 1.72 GW, Further Strengthening INNIO’s Data Center Backlog and Revenue Visibility22.10.2026 14:30:00 CEST | Press release
Customer also signs long-term full maintenance agreement for first 500 MW, expanding INNIO’s recurring services base. INNIO N.V. (Nasdaq: INIO) today announced a 620 megawatt (MW) follow-on order from a leading developer and operator of mega-scale data center campuses in the U.S. Together with the customer’s 1.1 gigawatt (GW) order announced in July 2026, the new order brings cumulative orders from the customer to approximately 1.72 GW, further strengthening INNIO’s order backlog and visibility into future revenues. “This follow-on order, coming just months after the customer’s initial 1.1 GW order, underscores the strength of customer demand and continued confidence in INNIO. Our containerized Jenbacher solutions deliver what data centers need most: fast deployment, high power density, fuel efficiency, and the performance to support demanding AI workloads,” said Dr. Olaf Berlien, President and CEO of INNIO. “Repeat orders of this scale, combined with long-term service agreements, stre
European Public Transport Budgets Require 36% Annual Spending Increase by 2035, Arthur D. Little and Polis Research Finds22.10.2026 14:30:00 CEST | Press release
Europe’s public transport sector currently accounts for €130 billion in annual expenditure, yet faces a growing funding gap as demand rises and environmental and resilience requirements intensify. New research from Arthur D. Little (ADL)’s Future of Mobility Lab and POLIS, a network of European cities and regions collaborating to develop innovative and sustainable urban transport solutions, outlines the scale of this financial shortfall and provides radical recommendations for overcoming it. Based on research with senior transport and policymakers, in-depth literature reviews, and real-world data from Paris, London, Amsterdam, Berlin and New York, the report estimates that additional spending will require a 36% increase in overall annual expenditure from now to 2035 onwards. This is made up of a 13% rise in operating expenditure (OPEX) and 56% in capital expenditure (CAPEX), driven by: Hidden debt caused by historic underinvestment in existing infrastructure (6% of additional funding n
Hitachi Report Examines Readiness for Physical AI in Industrial Companies22.10.2026 14:00:00 CEST | Press release
AI adoption progress, trends, and emerging priorities suggest opportunities and challenges for physical AI acceleration Hitachi, Ltd. (TSE:6501, "Hitachi") announced the release of its physical AI survey-based research report, Beyond the Pilot: Industry’s Physical AI Progression. The company surveyed over 200 global decision-makers from organizations operating in mission-critical industrial sectors including energy, manufacturing, transportation and logistics. The report explores how businesses today adopt AI in industrial use-cases, where they see the greatest value, and what it will take to scale toward physical AI deployments. Readers will gain practical insights on how to accelerate AI adoption while improving competitiveness, productivity, and long-term business performance. After successfully transforming knowledge work, AI is now entering the physical systems that form society’s backbone: energy, industrial, and mobility infrastructure, to name a few. Given these systems’ reliab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom